Novel topical/dermal Fenoldopam mesylate formulations reduce significantly the in vitro secretion of eight cytokines: tumor necrosis factor‐α (TNF‐α), interferon‐γ (IFN‐γ), interleukin‐1β (IL‐1β), IL‐2, IL‐4, IL‐6, IL‐8 and IL‐10, by CD3/CD28‐activated CD3+ normal human T cells of healthy subjects. Data represent mean ± SD (n = 3). Statistical analysis was performed by Kruskal–Wallis test. Statistical significance was set at P < 0·05.